Discontinued — last reported Q4 '17
Finite Lived Intangible Assets - Gross
Pfizer Finite Lived Intangible Assets - Gross increased by 0.3% to $104.85B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.0%, from $103.84B to $104.85B. Over 4 years (FY 2020 to FY 2024), Finite Lived Intangible Assets - Gross shows an upward trend with a 7.7% CAGR.
Analysis
How to read this metric
An increase typically signals recent strategic acquisitions or significant investment in intellectual property, while a decrease reflects asset retirement or impairment.
Detailed definition
This is the total historical cost of intangible assets with a defined useful life, such as patents, trademarks, and acqu...
Peer comparison
Large healthcare companies frequently carry significant gross intangible assets due to the high volume of M&A activity in the sector.
finite_lived_intangible_assets_grossHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $77.58B | $77.35B | $76.55B | $76.44B | $76.32B | $76.04B | $88.76B | $88.32B | $89.38B | $89.29B | $102.94B | $104.05B | $103.96B | $103.84B | $103.40B | $103.40B | $104.55B | $104.85B |
| QoQ Change | — | -0.3% | -1.0% | -0.2% | -0.2% | -0.4% | +16.7% | -0.5% | +1.2% | -0.1% | +15.3% | +1.1% | -0.1% | -0.1% | -0.4% | +0.0% | +1.1% | +0.3% |
| YoY Change | — | — | — | — | -1.6% | -1.7% | +16.0% | +15.5% | +17.1% | +17.4% | +16.0% | +17.8% | +16.3% | +16.3% | +0.4% | -0.6% | +0.6% | +1.0% |
Finite Lived Intangible Assets - Gross at Other Companies
Frequently Asked Questions
- What is Pfizer's finite lived intangible assets - gross?
- Pfizer (PFE) reported finite lived intangible assets - gross of $104.85B in Q3 2025.
- How has Pfizer's finite lived intangible assets - gross changed year-over-year?
- Pfizer's finite lived intangible assets - gross increased by 1.0% year-over-year, from $103.84B to $104.85B.
- What is the long-term trend for Pfizer's finite lived intangible assets - gross?
- Over 4 years (2020 to 2024), Pfizer's finite lived intangible assets - gross has grown at a 7.7% compound annual growth rate (CAGR), from $76.76B to $103.40B.
- What does finite lived intangible assets - gross mean?
- The total original cost of intangible assets that have a limited lifespan, before subtracting accumulated amortization.